Medicare GLP 1 Bridge Claims Skip Part D and Start With a Rejection

Medicare patients who qualify for the Medicare GLP 1 Bridge pay $50 a month for certain obesity drugs, but the claim never touches their Part D plan. A Pharmacy Times report published October 26 says pharmacies that bill the Medicare GLP 1 Bridge like an ordinary Part D claim risk denials, upset patients and prescriptions left unfilled at the counter. The program started July 1, 2026, ends December 31, 2027, and has its own rules for who qualifies, which drugs count and how prior authorization works.

What the Bridge Covers and Who Qualifies

Federal law bars Medicare from paying for drugs used only for weight loss. CMS built the Medicare GLP 1 Bridge as a time limited demonstration to work around that ban, and it runs the program itself rather than through private drug plans, according to the Pharmacy Times report. It replaced an earlier CMS plan called BALANCE, which would have worked through Part D and Medicare Advantage plans from 2027 but drew too few plans. The Bridge covers weight management only. Four products qualify: Wegovy injection, Wegovy tablets, the Zepbound KwikPen and Foundayo tablets. Zepbound vials and the single dose Zepbound pen are left out, as are Ozempic, Rybelsus, Mounjaro and Trulicity. People who take a GLP 1 drug for diabetes, sleep apnea or another approved use stay on their usual Part D route.

To join, a patient must be at least 18 and signed up for a qualifying Part D plan. The clinical rules, drawn from UnitedHealthcare provider guidance cited in the report, rest on body mass index. A BMI of 35 or more qualifies on its own. A BMI of 30 or more qualifies alongside a related illness, for example heart failure with preserved ejection fraction, chronic kidney disease stage 3a or worse, or blood pressure that stays high despite two medicines. A BMI of 27 or more qualifies with criteria such as prediabetes. The program shuts out people who have type 2 diabetes, the liver disease MASH, established heart disease or moderate to severe sleep apnea, plus anyone already getting a GLP 1 through Part D. Our eligibility guide for the $50 copay walks through each rule.

Prior Authorization Starts With a Rejected Claim

The prescription decides where the claim goes. According to the Pharmacy Times workflow report, the prescriber needs to list a weight diagnosis from the E66 code group and write "Send to Bridge for weight management" on the order. If that line is missing, the claim may go to the patient's regular Part D plan instead, and those plans rarely cover weight loss drugs. Once the Bridge is billed, its first claim is designed to fail, and that rejection is what starts prior authorization. The pharmacy then passes the form to the prescriber, electronically or by fax, typically within one to three days. Prescribers are told to hold off for that request instead of filing with CMS directly, and to fax the CMS form themselves only if nothing shows up after 72 hours.

Once the Bridge is billed, its first claim is designed to fail, and that rejection is what starts prior authorization.

The report says a decision should reach both the prescriber and the patient no more than 72 hours after the form is sent. A central processor, rather than the patient's own plan, handles each request, and the benefits consultancy WTW reports that Humana does these reviews. After approval of the first fill, later refills go through without fresh paperwork, unless the patient changes to another covered drug. The report urges pharmacy teams to prepare a short script so that no one at the counter wrongly informs a patient that the drug is "not covered" after that first rejection. Some chains are adding staff help for this step, though our story on pharmacy prior authorization help found that one chain offers Bridge help only in some states. That early rejection is routine paperwork, not a refusal.

What Patients Pay and What Pharmacies Receive

Patients pay $50 a month. That payment sits outside the normal Part D money flow, the report says: no deductible applies first, the $50 earns no credit toward the yearly out of pocket cap, and low income subsidy help does not lower it. AARP, citing CMS, put the 2026 Part D spending limit at $2,100, and Bridge copays add nothing toward reaching it. CMS also says on its pharmacy guidance page that coupons and discount programs may not be applied to Bridge claims, whatever their funding source. For a retiree on a fixed income, that adds up to $600 over a full year with no cap protection, which the report calls a real barrier to staying on treatment.

On the other side of the counter, pharmacies receive $245 from CMS for each 30 day supply, according to WTW. The Pharmacy Times piece advises pharmacies to check that figure against the latest program instructions before they stock up, since the payment comes from the central processor rather than a Part D plan. The report lists four counter checks. Staff should look for the Bridge note and the E66 code before sending any claim, and make sure the product is one of the four covered forms, since a Zepbound vial will be refused. They should also screen for exclusions, above all sleep apnea and type 2 diabetes, because those patients belong in Part D. The last check is to explain the $50 copay and the approval timeline at the very first conversation.

The Coverage Cliff After 2027

The Bridge ends on December 31, 2027. Lawmakers have left the statutory ban on Medicare obesity drug coverage in place, and past efforts to lift it went nowhere, the report notes. When the program launched, CNBC reported that the future of coverage after 2027 was unclear. That leaves a coverage cliff for anyone who starts treatment under the Medicare GLP 1 Bridge in 2026 or 2027. Unless Congress or CMS acts, those patients could lose the $50 price in 2028 and face self pay costs instead. The report suggests pharmacists raise the end date at the first fill, so that patients and prescribers can plan for 2028 well before the last covered month arrives.

Paying cash is no easy fallback. Money spent that way builds no credit toward a deductible or a yearly spending limit, the report cautions, and an introductory price does not reflect what months of ongoing treatment will cost. Job based cover may not help either, since large employers are trimming obesity drug benefits for 2027, as our report on employer weight loss coverage cuts found. In the authors' view, the pharmacy counter is where this program succeeds or stalls. Staff spot a prescription without the Bridge note, catch an excluded pen or vial, explain why the first claim bounced and tell patients what they will pay. The authors also stress watching refill dates so patients do not run short between fills. This story is for information only and is not medical or coverage advice.

Conclusion

The Medicare GLP 1 Bridge gives eligible Part D enrollees four obesity drug products for $50 a month until December 31, 2027, but only when the prescription, product and paperwork line up. A rejected first claim is a normal step, not a denial. The copay does not count toward the Part D cap, coupons cannot lower it, and nothing yet replaces the program in 2028. Patients, prescribers and pharmacy teams should plan for both the workflow and the end date.